Redeye comments on ExpreS2ion’s updated Phase I immunogenicity data for ES2B-C001, showing HER2-specific antibody responses in eight of nine evaluable patients alongside increasing antibody titres with repeated dosing and no safety concerns identified. We view the data as encouraging, supporting both the biological activity and safety profile of the candidate, and as a positive step toward further clinical validation as the study progresses to higher dose levels.
LÄS MER
